Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.45 |
| ▸ | CALML3 | P27482 | 6/20 | 0.42 |
| ▸ | MAOA | P21397 | 9/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3080417 | 0.90 | CALML3 (0.45) | CALML3MAOAMAOBCYP3A4CYP2C19 | |
| SCHEMBL12075305 | 0.88 | GRM2 (0.47) | GRM2CALML3MAOAMAOBCYP3A4 | |
| SCHEMBL3098925 | 0.85 | MAOA (0.56) | CALML3MAOAMAOB | |
| SCHEMBL3080498 | 0.77 | CALML3 (0.50) | CALML3MAOAMAOBCYP3A4CYP2C19 | |
| SCHEMBL1394094 | 0.77 | CALML3 (0.45) | GRM2CALML3MAOAMAOBCYP3A4 | |
| SCHEMBL1394603 | 0.77 | CALML3 (0.41) | CALML3MAOAMAOBCYP3A4CYP2C19 | |
| SCHEMBL1394249 | 0.76 | MAOA (0.40) | CALML3MAOAMAOBCYP3A4CYP2C19 | |
| SCHEMBL3088807 | 0.76 | CALML3 (0.45) | CALML3MAOAMAOBCYP3A4CYP2C19 | |
| SCHEMBL3092887 | 0.76 | CALML3 (0.43) | GRM2CALML3MAOAMAOBCYP3A4 | |
| SCHEMBL1392949 | 0.76 | CALML3 (0.38) | CALML3MAOAMAOBCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234591-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7705026-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090118502-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234591-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | GRM2 3878/4885CALML3 3842/4885MAOA 872/4885 |
| US-20090118502-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | GRM2 3878/4885CALML3 3842/4885MAOA 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.